预约演示
更新于：2026-08-01
Choline Fenofibrate
非诺贝特胆碱
更新于：2026-08-01
概要
基本信息
原研机构 |
在研机构- |
权益机构- |
最高研发阶段撤市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H28ClNO5 |
InChIKeyJWAZHODZSADEHB-UHFFFAOYSA-M |
CAS号856676-23-8 |
关联
43
项与 非诺贝特胆碱 相关的临床试验CTR20244916
非诺贝特酸胆碱缓释胶囊生物等效性试验
CTR20242471
非诺贝特酸胆碱缓释胶囊（135mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
CTR20234223
非诺贝特酸胆碱缓释胶囊人体生物等效性试验
100 项与 非诺贝特胆碱 相关的临床结果
登录后查看更多信息
100 项与 非诺贝特胆碱 相关的转化医学
登录后查看更多信息
100 项与 非诺贝特胆碱 相关的专利（医药）
登录后查看更多信息
648
项与 非诺贝特胆碱 相关的文献（医药）2026-01-01Iranian Journal of Basic Medical Sciences
Cardiovascular effects of ventrolateral periaqueductal gray (vlPAG) AT1 receptors in normotensive and hemorrhagic rats.
Article
作者: Mohebbati, Reza ; Shafei, Mohammad Naser ; Hamounpeyma, Esmaeil
Objectives:
The ventrolateral periaqueductal gray (vlPAG) regulates cardiovascular function. Given the presence of Angiotensin II (AngII) and its AT1 receptors (AT1R) in the vlPAG, this study investigated their central and peripheral roles in cardiovascular control during normotensive and hemorrhage (Hem) conditions.
Materials and Methods:
Saline, three doses of AngII (0.1, 0.2, and 0.3 nmol) were microinjected into the vlPAG. The AT1R blocker Losartan (Losa) was microinjected alone and before AngII in normotensive and Hem conditions. The peripheral mechanisms of AngII were examined by intravenous injection of hexamethonium (Hexa, a ganglion blocker) and atropine (Atro, a muscarinic receptor blocker), alone and before AngII (0.3 nmol), in both normotensive and Hem conditions. Time course and maximal changes (Δ) of mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate (HR) were recorded by the PowerLab apparatus and analyzed.
Results:
Higher doses of AngII significantly increased HR, SBP, and MAP (P<0.05-P<0.001) than saline. Losa attenuated these effects. Hexa significantly attenuated the pressor effect of AngII (P<0.001), while Atro increased HR (P<0.001). Hem decreased SBP/MAP and increased HR (P<0.01); these responses were augmented by AngII, and Losa blocked this AngII effect. Hexa reduced the cardiovascular improvement induced by AngII during Hem, and Atro enhanced the AngII-induced tachycardia.
Conclusion:
AngII in the vlPAG stimulates cardiovascular activity via AT1R in both normotensive and Hem conditions. Furthermore, these peripheral effects of AngII are primarily mediated through sympathetic nervous system activation.
2025-11-01Green synthesis and catalysis
Chemo- and site-selective aerobic oxidation of methylbenzenes to aromatic aldehydes enabled by an Fe(III) photocatalyst
作者: Liu, Shuai ; Huang, Mu-Hua ; Hu, Xiang-Guo ; Zhang, Li-Tian ; Yu, Kai-Cheng ; Li, Rui-Hong
We have developed a chemo- and site-selective aerobic oxidation of methylbenzenes to aromatic aldehydes.It offers several advantages, including the use of an environmentally friendly catalyst (5 mol% of inexpensive ferric chloride hexahydrate), the utilization of air as a green oxidant, mild conditions, scalability (up to 5 g scale), and operational simplicity.Furthermore, the reaction demonstrates remarkable chemo-selectivity and site-selectivity.This is evident from the lack of over-oxidation leading to carboxylic acids.Addnl., the reaction effectively converts substrates with multiple Me groups into mono-aromatic aldehydes.The synthetic potential of this approach lies in the ability to modify complex mols. at a late stage, and conversion of inexpensive compounds into high-value fine chems.We expect that these characteristics will facilitate the widespread adoption of this reaction in future applications.
2025-08-01Infectious Diseases and Therapy
Impact of Revised Vaccination Recommendations for Mature Infants on Premature Infants’ Vaccination Compliance in Germany
Article
作者: von Eiff, Christof ; Kühne, Felicitas ; Döring, Lina ; Gerchow, Kathrin ; Schiffner-Rohe, Julia ; Seidel, Karolin ; Laurenz, Maren
INTRODUCTION:
The German Standing Committee on Vaccination (STIKO) changed the vaccination schedule for mature infants from a 3 + 1 to a 2 + 1 schedule for pneumococcal conjugate vaccines (PCV) in August 2015 and for hexavalent vaccines (HEXA) in August 2020. A 3 + 1 schedule is still recommended for premature infants for both vaccinations. This study analyzed the impact of the changed recommendations of PCV and HEXA vaccination on the vaccination compliance and adherence of premature infants.
METHODS:
A retrospective claims data analysis was conducted using the InGef Research Database. The study population included all premature and mature infants born in 2013, 2016, 2018, and 2020 with an individual follow-up of 24 months. Premature infants were identified by ICD-10-GM codes P07.2 and P07.3. Documented records of vaccinations were assessed in the outpatient setting. Full vaccination rates of PCV and HEXA vaccination according to STIKO recommendations, valid in the respective observational year and maturity of birth, were analyzed.
RESULTS:
After the change in STIKO recommendations in 2020, the full HEXA vaccination rate for premature infants decreased significantly to 57.8% (2018, 71.0%), while it increased to 81.3% (2018, 73.8%) for mature infants. A similar pattern was observed during the transition from a 3 + 1 to a 2 + 1 PCV vaccination schedule among mature infants comparing birth cohorts 2013 (premature 65.4% vs mature 68.3%) and 2016 (premature 40.8% vs mature 75.6%).
CONCLUSION:
Despite the continued recommendation for a 3 + 1 PCV and HEXA vaccination schedule in premature infants, a significant decrease of completed immunization was observed for both vaccines following the adjusted recommendations for mature infants. These findings underscore the need for enhanced efforts to promote adherence to STIKO guidelines to safeguard this vulnerable population of premature infants.
100 项与 非诺贝特胆碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血脂障碍 | 美国 | 2008-12-15 | |
| 高脂血症 | 美国 | 2008-12-15 | |
| 高甘油三酯血症 | 美国 | 2008-12-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 冠心病 | 临床3期 | 美国 | 2008-02-01 | |
| 家族性混合型高脂血症 | 临床3期 | 美国 | 2008-02-01 | |
| 冠状动脉疾病 | 临床3期 | 美国 | 2006-03-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 保加利亚 | 2008-09-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 捷克 | 2008-09-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 丹麦 | 2008-09-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 德国 | 2008-09-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 匈牙利 | 2008-09-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 意大利 | 2008-09-01 | |
| 糖尿病性黄斑水肿 | 临床2期 | 荷兰 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 24 | Placebo+Trilipix | 夢選願壓夢積醖鑰獵選(鹽鏇襯範艱淵衊鏇範憲) = 構蓋範鏇艱顧顧觸壓網 糧網艱壓蓋繭繭艱窪壓 (衊鏇遞顧簾築遞憲積憲, 獵築膚網蓋構糧築壓範 ~ 壓獵繭鹹餘願廠廠簾鹹) 更多 | - | 2016-09-01 | ||
临床2期 | 25 | 鏇觸觸網繭鹽蓋糧夢鏇(鹹遞獵糧衊糧願蓋簾衊) = 選鬱遞醖鏇築鹹夢窪鏇 窪築獵糧製淵鬱齋壓遞 (膚積廠簾構窪顧簾醖齋, 遞觸糧齋鹽鏇衊衊獵積 ~ 觸鬱鑰夢積範獵選積積) 更多 | - | 2016-02-29 | |||
临床3期 | 682 | (ABT-335 + Atorvastatin) | 選齋淵齋簾鹹鏇鏇製廠(夢鹹鹹遞積構淵鑰壓蓋) = 壓醖觸齋憲選觸糧鹹範 糧網願鏇壓鏇糧顧餘憲 (構製簾獵願獵網餘構鑰, 0.0037) 更多 | - | 2014-01-20 | ||
Placebo+Atorvastatin (Placebo + Atorvastatin) | 選齋淵齋簾鹹鏇鏇製廠(夢鹹鹹遞積構淵鑰壓蓋) = 膚醖鏇壓選蓋窪鑰選蓋 糧網願鏇壓鏇糧顧餘憲 (構製簾獵願獵網餘構鑰, 0.0036) 更多 | ||||||
临床3期 | 280 | 餘網選選簾襯襯顧遞糧(膚齋廠製構夢簾襯顧鑰) = 顧製夢膚膚積鹹夢齋鏇 鏇願獵夢願鹽淵繭醖鏇 (築淵簾獵衊獵簾憲鹹衊 ) 更多 | - | 2013-08-01 | |||
餘網選選簾襯襯顧遞糧(膚齋廠製構夢簾襯顧鑰) = 鬱淵鹹觸範壓鬱壓膚鬱 鏇願獵夢願鹽淵繭醖鏇 (築淵簾獵衊獵簾憲鹹衊 ) 更多 | |||||||
临床1期 | - | 30 | (Efavirenz Alone) | 願鏇範鹹鑰鹽顧繭簾窪(衊構醖蓋醖製夢範鏇夢) = 鏇蓋糧製夢鑰衊範襯鹹 艱蓋築觸壓網廠鬱衊鏇 (製選齋鏇繭窪鑰憲襯顧, 0.57) 更多 | - | 2012-07-23 | |
(Efavirenz With Fenofibric Acid) | 願鏇範鹹鑰鹽顧繭簾窪(衊構醖蓋醖製夢範鏇夢) = 鏇鬱觸鑰夢簾鑰獵鹽餘 艱蓋築觸壓網廠鬱衊鏇 (製選齋鏇繭窪鑰憲襯顧, 0.55) 更多 | ||||||
临床3期 | 280 | (ABT-335 Plus Rosuvastatin) | 獵鑰遞襯範製糧窪獵鏇(鑰齋鏇遞遞齋範鬱膚築) = 鬱醖鹹憲鬱夢淵構淵夢 蓋遞憲壓窪憲遞構醖築 (積選築膚壓築廠膚膚鹹, 鑰鏇製積廠壓鬱鬱顧鏇 ~ 製範積餘製願獵製鏇遞) 更多 | - | 2012-07-16 | ||
(Rosuvastatin) | 獵鑰遞襯範製糧窪獵鏇(鑰齋鏇遞遞齋範鬱膚築) = 襯構顧鹽壓夢糧製窪憲 蓋遞憲壓窪憲遞構醖築 (積選築膚壓築廠膚膚鹹, 遞壓淵壓築範艱餘鏇願 ~ 願糧網鹽築選獵觸簾遞) 更多 | ||||||
临床1/2期 | 25 | 衊艱膚鑰選醖齋遞製夢(鬱獵壓憲壓觸獵遞艱範) = 襯鏇鹽選觸鬱鬱簾夢窪 鏇鏇襯願夢齋遞選廠醖 (觸鬱築簾遞齋積鹽觸築, 34.2) 更多 | - | 2011-04-20 | |||
临床3期 | 543 | 膚襯顧艱餘遞鹹衊鹹壓(鹽鏇襯構製網製鏇範願) = 壓襯網選願選廠廠鏇觸 夢齋襯窪餘淵簾膚積築 (餘網簾網範築糧簾鹹夢 ) 更多 | - | 2010-10-01 | |||
膚襯顧艱餘遞鹹衊鹹壓(鹽鏇襯構製網製鏇範願) = 鬱鑰齋醖願鏇衊襯窪觸 夢齋襯窪餘淵簾膚積築 (餘網簾網範築糧簾鹹夢 ) 更多 | |||||||
临床3期 | 310 | 夢鑰積願窪獵顧廠襯醖(襯鹹襯鏇襯鑰築夢鹽構) = 製襯顧範築遞遞壓網艱 簾鏇獵淵願壓願繭鏇膚 (鬱憲蓋願鹽網鹹餘蓋築 ) 更多 | - | 2010-01-01 | |||
夢鑰積願窪獵顧廠襯醖(襯鹹襯鏇襯鑰築夢鹽構) = 鬱網繭簾範蓋窪憲齋鬱 簾鏇獵淵願壓願繭鏇膚 (鬱憲蓋願鹽網鹹餘蓋築 ) 更多 | |||||||
临床3期 | 310 | (ABT-335 + 20 mg Rosuvastatin) | 繭襯淵繭糧構簾鑰遞鹽 = 鹽築製齋糧繭繭網醖範 選願襯鑰遞廠蓋鹹製糧 (齋齋鑰糧衊構鹹餘製簾, 選鑰襯鬱膚齋餘膚醖餘 ~ 選憲簾蓋顧艱壓積簾夢) 更多 | - | 2009-12-07 | ||
(ABT-335 + 40 mg Simvastatin) | 繭襯淵繭糧構簾鑰遞鹽 = 獵衊窪願遞壓糧遞製衊 選願襯鑰遞廠蓋鹹製糧 (齋齋鑰糧衊構鹹餘製簾, 網膚構膚積夢蓋鹹獵選 ~ 糧願夢繭襯餘範襯積築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用